WuXi Biologics (Cayman) Inc. disclosed a Next Day Disclosure Return dated 11 November 2025, indicating the issuance of new ordinary shares under its Pre-IPO Share Option Scheme adopted on 5 January 2016 (as amended on 10 August 2016). A total of 20,000 new ordinary shares were allotted for share options granted to a participant, and 4,500,000 new ordinary shares were issued for share options granted to a company director. Both tranches were issued at HKD 1.29 per share.

Following these changes, the company’s issued share capital increased from 4,079,107,254 shares to 4,083,627,254 shares. The new shares together represent approximately 0.11081% of the preceding total issued share count. The announcement confirms that the issuance process complied with relevant legal and regulatory requirements, and there were no on-market share repurchases or sales of treasury shares to report.